Kornimate/medical-research-clean huggingface dataset:
mechanisms of exposure therapy for ocd

Conditions: Obsessive-Compulsive Disorder

Summary: exposure therapy is the most effective treatment available for obsessive compulsive disorder, yet up to 50% of patients do not recover because the mechanisms underlying successful response are poorly understood, leading to significant variability in how clinicians conduct exposure therapy. the main purpose of this study is to determine which target mechanisms are most critical to engage in real-world exposure sessions to produce good treatment outcomes. adult participants (n = 400) with obsessive compulsive disorder (ocd) receiving exposure therapy from two sites (mclean hospital, san diego state university) across the continuum of care (outpatient, partial hospital, residential) will complete baseline clinical and demographic measures as well as weekly symptom reports. the project will measure exposure mechanisms across three levels of analysis (self-report, observer-rated behavior, physiology) during each exposure session. mechanisms assessed will include a broad range of variables based on both habituation and inhibitory learning models of exposure. self-report and observer-rated mechanisms will be measured with the exposure feedback form, created and piloted by the study team. physiological mechanisms will include skin conductance response, heart rate, and heart rate variability measured with a wristwatch. the current study will determine (1) which exposure mechanisms lead to favorable clinical outcomes, and (2) what makes a good exposure for whom. results of this study have the potential to improve personalized care for the many patients who do not remit following exposure therapy for ocd.


Eligibility criteria:
inclusion criteria: * between the ages of 18-65 years old * seeking exposure treatment at mclean hospital ocd institute or san diego state university * have a diagnosis of ocd * able to complete study measures and treatment procedures in english exclusion criteria: * acute symptoms of psychosis * active suicidality (plan, means, intent and/or suicide attempt in past 3 months) * presence of co-occurring symptoms that warrant higher level of care (e.g., inpatient treatment) * presence of any medical, psychiatric, or developmental condition that would prevent patients from completing assessments or exposure exercises (e.g., non-verbal autism spectrum disorder)
a study of tasisulam-sodium versus paclitaxel as treatment for metastatic melanoma

Conditions: Melanoma

Summary: the primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.


Eligibility criteria:
inclusion criteria: * have a histologic and/or cytologic diagnosis of metastatic melanoma (stage iv). * have the presence of evaluable disease as defined by the response evaluation criteria in solid tumors (recist 1.0). * have a performance status of 0-1 on the eastern cooperative oncology group (ecog) scale. * have progressed after 1 previous systemic treatment containing dacarbazine or temozolomide for metastatic melanoma. * have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, or other investigational therapy for at least 30 days (6 weeks for mitomycin-c or nitrosoureas) before study enrollment and recovered from the acute effects of therapy (except alopecia). * have a serum albumin level greater than or equal to 3.0 grams per deciliter (g/dl) or greater than or equal to 30 grams per liter (g/l). exclusion criteria: * have received greater than or equal to 2 previous chemotherapy-containing systemic treatment regimens for metastatic melanoma. an immunotherapy or antibody-based regimen (including biologic agents and vaccination-based treatments), or treatment with a targeted agent (for example, braf or c-kit inhibitor is not counted as a prior treatment regimen for determining study eligibility, unless either was combined with a cytotoxic drug). * have active central nervous system (cns) or leptomeningeal metastasis (brain metastasis) at the time of study entry. participants with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before study entry to rule out occult brain metastasis. participants with a history of a solitary cns metastasis previously treated with curative intent (for example, stereotactic radiation or surgery) and not requiring steroids are eligible. * are receiving warfarin. * have primary ocular or mucosal melanoma. * any previous treatment with paclitaxel or a paclitaxel-containing regimen for metastatic melanoma. * have serious concomitant disorders, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the investigator). * have previously completed or withdrawn from this study or any other study investigating tasisulam-sodium. * have a known hypersensitivity to paclitaxel or cremophor el (polyoxyethylated castor oil). * are pregnant or lactating. * have received a recent (within 30 days before enrollment) or are receiving concurrent yellow fever vaccination. * have known positive test results in human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c antibodies (hcab). * are unable to withhold dosing of non-steroidal anti-inflammatory drugs (nsaids) or proton-pump inhibitors (ppis) for at least 72 hours before and after treatment with tasisulam-sodium.

Keywords: metastatic second-line
evaluation of the effectiveness of night orthosis in treating women with symptomatic osteoarthritis in the interphalangeal joint of the dominant hand

Conditions: Hand Injuries

Summary: evaluation of the effectiveness of using a night orthosis for ii and iii or fingers of the dominant hand in women diagnosed with symptomatic osteoarthritis compared to a control group.

objective: to evaluate the effectiveness of using a night orthosis for ii and iii or fingers of the dominant hand in women diagnosed with symptomatic osteoarthritis compared to a control group. methods: through a randomized controlled clinical trial with blind assessment and follow-up of six months. fifty-two participants were randomized into two groups: group orthosis and control, and made a night orthosis ii and or iii fingers, thermoplastic will be used as a treatment for participants orthosis group. the participants underwent four evaluations at time 0, 45 days, 90 days and 180 days after its inclusion in the study. the variables studied were: the visual analog scale of pain, grip and pinch strength, questionnaires cochin and australian/canadian hand osteoarthritis index and functional pick-up test.

Eligibility criteria:
inclusion criteria: * women aged between 40 and 80 years. * patients diagnosed with osteoarthritis (oa) hand according to the american college of rheumatology classification criteria. * pain symptom in proximal interphalangeal (pip's) or distal interphalangeal (dip's) dominant hand in ii and iii or fingers. * provide greater pain symptom of ii and iii or fingers between each other. * complains of pain symptom measured by a visual analog scale (vas) pain between 3 to 8 cm in the ii and iii or fingers of the dominant hand reported to perform joint movement (activity). * thumb abduction with the ii and iii fingers without changing the pincer movement pulp-pulp. exclusion criteria: * other rheumatic diseases, neurological and skeletal muscle that can affect the upper limb. * fibromyalgia uncontrolled. * pregnancy. * geographical inaccessibility and transport. * cognitive impairment that prevents the understanding of assessment tools.
low-intensity focused ultrasound for cocaine use disorder

Conditions: Cocaine Use Disorder; Cocaine Dependence; Cocaine Abuse; Ultrasound

Summary: this study aims to understand the role of low-intensity focused ultrasound on craving levels for cocaine as evidenced by diagnostic imaging of the dorsal anterior insula (dai) and subjective ratings. data analysis will serve to show if 1) lifu is safe and effective and to 2) examine the effects of lifu on dai bold activity and craving in response to cocaine cue-exposure. the study will screen 60 individuals with cocaine use disorder (cud) to arrive at 30 enrolled subjects, based on a 2:1 screen/randomization ratio.

this is a randomized single-blind, active, sham-controlled study. this study will enroll thirty (30) individuals, aged 18 years and older, that meet the criteria for cud. participants will be recruited from the general population and will be asked to complete cognitive testing and measures, self-reported craving measures, and diagnostic exams including magnetic resonance imaging (mri) and computed tomography (ct). participants will also undergo functional mri which entails being shown cocaine-related photos at regular intervals. all participants will receive lifu and sham interventions, but will be randomized to one of two sessions, and will return one month after the second session for an in-person follow-up. in total, there are five (5) in-person visits and two (2) phone calls to assess for adverse events, conducted over eight (8) weeks.

Eligibility criteria:
inclusion criteria: * ages 18 years and older with a history of cocaine use disorder * have a current (past 6 months) dsm-5 diagnosis of cocaine use disorder (4 or more symptoms) assessed using the mini neuropsychiatric interview * have a blood alcohol content by breathalyzer, equal to 0.000 when informed consent document is signed * ability to abstain from cocaine use at key points during study * willingness and ability to comply with scheduled visits and study procedures * ability to lie down for extended periods of time for imaging tests * will have reliable transportation throughout study * will have a stable residence during the 2 weeks prior to randomization and not be at risk of losing housing in next 2 months * must meet criteria to have magnetic resonance imaging (mri) exclusion criteria: • please contact pi or study coordinator for more details.

Keywords: substance use disorders chemically-induced disorders substance-related disorders cocaine addiction cocaine
evaluation of deep anterior lamellar keratoplasty by anterior segment ocular coherence tomography

Conditions: Keratoconus; Cornea; Corneal Opacity

Summary: investigators' research is concerned observing the post-operative anterior segment oct changes throughout the post- operative follow up of the patient and relating to improve the visual outcome of the surgery which is the goal of surgery

study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): * complete medical and ocular history, including patients' age, sex, type of pathology of the cornea such as keratoconus, opacity , history of previous corneal intervention , and other ocular surgeries. * thorough ophthalmological examination, including visual acuity, intraocular pressure (iop) measuring by goldman applanation tonometer (haag streit, koeniz, switzerland), slit lamp biomicroscopic examination of anterior segment, investigations for keratoconus as pentacam , preoperative anterior segment oct if needed , slit lamp photography for the cornea . candidate patients will be operated through dalk , then will be examined post operative clinically and be followed up at 3 months , 6 months for best corrected visual acuity, intraocular pressure , refraction , graft healing , and anterior segment oct for the anterior chamber angel , graft healing , descemet's membrane state , tear film . the interpretation of the clinical data with the changes in the ant. segment oct will give us the clue to get the best visual outcome of surgery . 2.4.5 -research outcome measures: 1. primary (main): to evaluate the post-operative changes after dalk surgery through ant segment oct and its relation to clinical findings. 2. secondary (subsidiary): to improve the outcome of the surgery through the graft creation , stitching of the graft , following up the iop clinically and state of ac angel through oct , the tear film and changes after surgery , all these factors to improve the target of the surgery which is the post operative best corrected visual acuity . data collection data to be collected include patients' age, sex, cause of corneal surgery ,bcva, iop levels, clinical examination of the eye and if there are findings , and ant. segment oct of the eye computer software data analysis will be done via spss version 26 windows 10 statistical tests data will be statistically described in terms of mean, sd, and range when appropriate. comparisons between the preoperative and postoperative data will be done using student's t-test. study groups' comparisons will be done using student's t-test for independent normally distributed samples data.

Eligibility criteria:
inclusion criteria: * patients undergoing dalk surgery older than 18 years old ( keratoconus and corneal opacity ). exclusion criteria: * patients suffering from active corneal ulcer * active infection. * posterior segment diseases. * recent ocular surgery in the study eye in the 2 months prior to enrolment, * media opacities as vitreous haemorrhage, * vasculitis , patients with macular edema related to, glaucoma, chronic uveitis, or pre-existing ocular pathologic features or abnormalities.
mindfulness-based stress reduction versus lifestyle intervention for long-haul covid-19 parosmia

Conditions: COVID-19

Summary: olfactory dysfunction (od) is a defining symptom of covid-19 infection. as the number of total, confirmed novel coronavirus sars-cov-2 (covid-19) cases exceeds 45 million in the united states, it is estimated that up to 85% of infected patients will experience at least some olfactory dysfunction. therefore, we propose a pilot single-site clinical trial to explore the efficacy of mbsr for covid-19-related smell distortion (parosmia)

the perception of distorted smell in the presence of a familiar odor is referred to as parosmia. parosmia can severely impair appetite and quality of life as familiar smells can trigger a foul smell. parosmia is increasingly recognized as a long covid symptom. intranasal and oral corticosteroids, theophylline, vitamin a, and omega-3 have all been proposed as treatment options for post-viral od. budesonide steroid irrigation paired with olfactory training, another avenure for treating olfactory loss, has shown some benefit compared with olfactory training alone. however, these treatments have demonstrated limited efficacy for patients with parosmia. mindfulness-based stress reduction (mbsr) is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. it is a practice that is embedded in mind/body and integrative medicine to cultivate psychological and emotional resilience. mbsr improves anxiety, depression, insomnia, and other psychological outcomes in clinical trials. although mbsr is one of the most widely practiced and extensively studied meditation programs in the world, its mechanism of benefit for patients with parosmia has not yet been assessed. in this phase ii trial, patients will be allocated 1:1 to receive either a mindfulness-based stress reduction course or a lifestyle management course. the courses will meet virtually once per week for 8 consecutive weeks as well as a one-time 4 hour virtual retreat.

Eligibility criteria:
inclusion criteria: * adults between the ages of 18 to 65 years * reside within the continental united states * ability to engage in virtual group sessions for 2 hours either tuesday or wednesday evenings for 8 consecutive weeks and the 1/2 day weekend retreat. * clinically diagnosed or subjective parosmia of at least 3 months duration after covid- 19 infection exclusion criteria: * clinically diagnosed olfactory dysfunction secondary to non-covid-19 viral infection, genetic abnormalities, congenital dysfunction, trauma, nasal polyps, or neurodegenerative disorders. * availability less than 4 months from time of enrollment * residency outside the continental united states * history of substance abuse, ptsd, thoughts of self-harm, or other active poorly controlled psychiatric or psychological conditions * sinus surgery in the 6 weeks prior to enrollment

Keywords: parosmia
evaluation of the efficacy and safety of lubiprostone in adults with mixed or unsubtyped irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: a study of the efficacy and safety of lubiprostone in subjects diagnosed with ibs-m/ibs-u.

to assess the efficacy and safety of oral lubiprostone, as compared to matching placebo, when administered orally (at 8 mcg twice daily \[bid\]) in subjects diagnosed with ibs-m/ibs-u.

Eligibility criteria:
inclusion criteria: * subject meets the diagnosis of ibs-m or ibs-u as confirmed using the adapted rome iii diagnostic questionnaire for adult functional gi disorders. * subject screening diary entries must show an average worst abdominal pain in the past 24 hours score of at least 4 on a 11-point scale. * subject must be on a stable dose of selective serotonin re-uptake inhibitors (ssris), serotonin-specific reuptake inhibitor (snris), or monoamine oxidase inhibitors (mao) inhibitors if taking antidepressants. exclusion criteria: * subject has current diagnosis of ibs with diarrhea (ibs-d) or ibs with constipation (ibs-c), according to rome iii criteria. * any gastrointestinal (gi) condition, other than ibs-related, affecting gi motility or defecation. * medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.
a phase 1 dose escalation study of amg 780 in adult subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a first in human, open-label, sequential dose escalation and expansion study of amg 780 in up to 62 subjects with advanced solid tumors. the dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of amg 780. the dose expansion will consist of up to 20 subjects and the dose level of amg 780 will be dependent upon emerging safety and pk data from the dose escalation part of the study.


Eligibility criteria:
inclusion criteria: * men and women ≥ 18 years old * must have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available, or for subjects who refuse standard therapy * measurable disease by recist criteria * must be able to undergo mri evaluation * eastern cooperative oncology group (ecog) performance status ≤ 2 * competent to sign and date an institutional review board approved informed consent form exclusion criteria: * presence of untreated or symptomatic primary central nervous system tumors or metastases * presence of leukemia or myelodysplastic syndrome * subjects with head and neck cancer * previous hematopoietic stem cell transplant (allogeneic) * unresolved hematological toxicities \> grade 1 with the exception of grade 2 lymphopenia and non-hematological toxicities \> grade 1, excluding alopecia and grade 2 neuropathy, from prior anti-cancer therapy * myocardial infarction within 1 year before study day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function * history of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study * active peripheral vascular disease * history of bleeding diathesis * history of pulmonary hemorrhage or gross hemoptysis within 6 months before study * known history of adrenal hemorrhage * known positive test for human immunodeficiency virus infection, or active hepatitis b or hepatitis c * major surgery within 1 month before study * prior treatment with any agent targeting the angiopoietin-tie2 signaling pathway * concurrent antitumor treatment, except lupron for subjects with prostate cancer and selective estrogen receptor modulators (serms) for subjects with breast cancer, within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1 * known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing * investigational agent within 30 days before study * pregnant (eg, positive urine test) or breastfeeding * subjects of childbearing potential, or subject who has a partner of childbearing potential, and is not using highly effective contraceptive precautions

Keywords: first-in-human dose escalation dose expansion advance solid tumors anti-angiopoietin advance malignancy cancer oncology oncology patients phase 1 clinical trial tumors solid tumors angiogenesis inhibitors
evaluate the port-wine stain birthmark treatment before and after pulsed dye laser treatment

Conditions: Port-wine Stain

Summary: port-wine stain is a congenital, progressive vascular malformation of human skin involving post-capillary venules that occurs in an estimated 0.3% of children and can alter personality development and psychological in children.

the researchers at university of california, irvine and washington university in saint louis are collaborating in this project and developes new multiple imaging devices call photoacoustic microscopy and optical coherence tomography imaging technologies can be use to evaluate the response of port-wine stain from pulse dye laser treatment.

Eligibility criteria:
inclusion criteria: * all age with diagnosis of port-wine stain exclusion criteria: * no diagnosis of port-wine stain
right lateral positioning of postoperative pediatric cardiac surgery

Conditions: Heart Defects, Congenital

Summary: directly following cardiac surgery for congenital heart disease; patients are not receiving routine turning every two hours to prevent pressure ulcers, because a negative influence on hemodynamic parameters is assumed. investigators have suggested that lateral position may have clinically significant effects on oxygenation in cardiac surgery patients.

sixty pediatric congenital heart disease patients were randomly assigned to two equal intervention groups

Eligibility criteria:
inclusion criteria: * age within 10 years with a cyanotic congenital heart disease * hemodynamic stability with no compromising arrhythmia * no respiratory arrest * not connected with mechanical ventilation exclusion criteria: * cyanotic congenital heart disease * hemodynamic instability

Keywords: right lateral oxygenation cardiac congenital pediatric postoperative